MOMaria Christina Lopes Oliveira

Maria Christina Lopes Oliveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Christina Lopes Oliveira has a total of 68 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Risk Factors of COVID-19 Severity and Related Death in Children in the Post-Pandemic Era

    by Laura G. Coelho, Lilian M. Diniz, Stella C. Galante, Cristiane S. Dias, Maria Christina L. Oliveira, Enrico A. Colosimo, Ana Cristina Simões e Silva, Fernanda N. Duelis, Maria Eduarda T. Bernardes, Julia O. Zavitoski, et al.

    In the post-pandemic era, identifying children who are most susceptible to severe illness and COVID-19-related mortality is essential for guiding public health policies. This study examined the risk factors for COVID-19-related severe illness and mortality from 2023 to mid-2025. We conducted a population-based cohort study using nationwide Brazilian data from patients aged p < 0.001) and death (aOR = 2.1; 95% CI: 1.3–3.5; p < 0.001). In the post-pandemic era, younger age, comorbidities, sociodemographic disparities, and lack of vaccination were associated with an increased risk of severe illness and COVID-19-related death in the pediatric population.


  • Open Access

    COVID-19 Vaccine Effectiveness in Individuals with Alcohol and Tobacco Use Disorders: A Propensity Score-Matched Study Using Nationwide Brazilian Data

    by Fabrício Emanuel S. Oliveira, Daniella R. B. Martelli, Maria Christina L. Oliveira, Enrico A. Colosimo, Ana Cristina Simões e Silva, Ana Livia O. Andrade, Rafaela R. Herrerias, Lays R. C. Foligno, Isabella O. Barbosa, Hercílio Martelli-Junior, et al.

    Background/Objectives: Individuals with alcohol use disorder (AUD) and tobacco use disorder (TUD) are at increased risk for severe COVID-19 outcomes. However, real-world evidence on vaccine effectiveness (VE) in these populations remains limited, particularly in low- and middle-income countries. This study aimed to evaluate the effectiveness of three or more COVID-19 vaccine doses against mortality in hospitalized patients with AUD and TUD in Brazil. Methods: This retrospective cohort study used data from the SIVEP Gripe database, a national surveillance system of hospitalized COVID-19 cases in Brazil. The study included adults aged ≥18 years with confirmed SARS-CoV 2 infection between February 2020 and June 2025. The intervention was defined as receipt of three or more vaccine doses (fully vaccinated) versus no doses (unvaccinated). Propensity score matching was performed separately for AUD and TUD cohorts. Vaccine effectiveness was estimated using McNemar’s test for paired samples, and the average treatment effect (ATE) and number needed to vaccinate (NNV) were calculated. Results: Among 2,184,723 hospitalized patients, 12,115 had AUD and 45,679 had TUD. After matching, VE against mortality was 42% (95% CI: 27.5–53.5) in the AUD group and 52.6% (95% CI: 46.5–58.1) in the TUD group, compared to 58.5% and 58.9% in their respective non-exposed counterparts. The ATE was consistent across groups (approximately −0.12), and the NNV to prevent one death was 8 (95% CI: 6–15 for AUD; 7–12 for TUD). Conclusions: Although VE was attenuated in individuals with AUD and TUD compared to the general population, the absolute benefit of vaccination remained substantial.

  • Open Access

    Effectiveness of COVID-19 Vaccine Boosters in Children Across Pandemic and Endemic Periods

    by Eduardo A. Oliveira, Maria Christina L. Oliveira, Hercílio Martelli-Júnior, Fabrício Emanuel S. Oliveira, Daniella R. B. Martelli, Rayner Santos, Robert H. Mak, Ana Cristina Simões e Silva, Lilian M. Diniz, Cristiane S. Dias, et al.

    In the SARS-CoV-2 endemic phase, assessing the effectiveness of COVID-19 booster doses in children is essential for public health policy. This study evaluated the vaccine effectiveness (VE) of three doses (primary series plus booster) against severe outcomes, comparing the pandemic and endemic periods and children with and without comorbidities. We carried out a cohort study based on the population, utilizing comprehensive Brazilian data from individuals under 18 years of age with confirmed SARS-CoV-2 infection, spanning from February 2020 to June 2025. The primary exposure of interest was three or more doses of COVID-19 vaccines. The primary outcome of interest was COVID-19-related death. VE and the number needed to vaccinate (NNV) to prevent one death were estimated in a propensity score-matched cohort, with adjustments for confounders. Among 3,730,007 reported pediatric cases, 5472 (0.1%) died, 99% of whom did not receive a booster dose. During the pandemic, the VE against death was higher in children with comorbidities (92.7% [95% CI, 63.5–99.0]; NNV = 23 [19–30]) than in those without (68.2% [25.7–86.4]; NNV = 2000 [1111–9774]). During the endemic period, the VE against death remained high and was comparable between groups: 89.4% (29.8–98.7) and 75.8% (36.4–95.7) for children with and without comorbidities, respectively. Nevertheless, NNV levels were significantly lower in children with comorbidities, reflecting an increased risk at baseline. Although booster doses continue to offer substantial protection against fatal COVID-19 outcomes, the magnitude of this benefit is directly correlated with the baseline risk. Consequently, these findings support the implementation of risk-based prioritization strategies in public health decision-making for children.


  • Open Access

    Effectiveness of COVID-19 Vaccines Against Hospitalization and Severe Disease in Children with Diabetes Mellitus During Pandemic and Post-Pandemic Eras

    by Laura G. Coelho, Lilian M. Diniz, Stella C. Galante, Cristiane S. Dias, Maria Christina L. Oliveira, Enrico A. Colosimo, Ana Cristina Simões e Silva, Fernanda N. Duelis, Maria Eduarda T. Bernardes, Daniela R. Martelli, et al.

    Pediatric patients with SARS-CoV-2 infection are at an increased risk of severe disease and adverse outcomes. Nevertheless, comprehensive data on COVID-19 vaccine effectiveness (VE) in children with diabetes during the post-pandemic period remain limited. This study assessed the VE against severe COVID-19 outcomes during both the pandemic and post-pandemic phases in children with and without diabetes mellitus (DM). A cohort study based on population data was carried out, including all patients under 18 years of age with symptomatic SARS-CoV-2 infection as registered in the Brazilian national surveillance systems from February 2020 to June 2025. The main outcomes were hospitalization due to COVID-19 and severe illness, which included admission to the intensive care unit (ICU), need for invasive ventilation, and death. Utilizing a propensity score-matched cohort, we estimated the VE and the number needed to vaccinate (NNV) for a booster dose against these outcomes by comparing vaccinated and unvaccinated individuals, employing conditional logistic regression adjusted for confounding variables. The cohort comprised 3,730,007 pediatric patients with COVID-19, of whom 7675 (0.2%) had DM. At baseline, children with DM exhibited a significantly higher prevalence of hospitalization (11.2% vs. 2.0%), severe COVID-19 (6.4% vs. 0.6%), and mortality (1.9% vs. 0.1%) than those without DM (all p < 0.001). During the pandemic period, the adjusted VE was consistently higher in children with DM. Against severe disease, the VE was 72.8% (95% CI: 12.3–93.2) in the DM cohort compared with 45.7% (28.1–59.0) in the non-DM cohort. This increased effectiveness corresponded to a more favorable NNV; the NNV to prevent one severe case was 24 (95% CI: 12–232) for children with DM versus 243 (168–440) for those without DM. In the post-pandemic period, the VE remained significantly higher in the DM cohort. Against severe disease, the VE was 76.2% (11.5–93.5) for children with DM and 52.9% (32.7–67.1) for those without. The NNV to prevent one severe case was consistently lower in the DM cohort (8 vs. 591). In conclusion, a complete vaccination regimen, including a booster dose, substantially mitigated severe COVID-19 outcomes in children with DM in the pandemic and post-pandemic periods.


  • Open Access

    COVID-19 Vaccine Effectiveness and Risk Factors of Booster Failure in 480,000 Patients with Diabetes Mellitus: A Population-Based Cohort Study

    by Maria Christina L. Oliveira, Daniella R. Martelli, Ana Cristina Simões e Silva, Cristiane S. Dias, Lilian M. Diniz, Enrico A. Colosimo, Clara C. Pinhati, Stella C. Galante, Fernanda N. Duelis, Laura E. Carvalho, et al.

    To investigate the real-world effectiveness of COVID-19 vaccines in a large cohort of patients with diabetes mellitus (DM), we analyzed all >18-year-old patients with COVID-19 registered in a Brazilian nationwide surveillance database between February 2020 and February 2023. The primary outcome of interest was vaccine effectiveness against death, evaluated using multivariate logistic regression models. Among the 2,131,089 patients registered in the SIVEP-Gripe, 482,677 (22.6%) had DM. After adjusting for covariates, patients with DM had a higher risk of death than those without comorbidities (adjusted odds ratio [aOR] = 1.43, 95% CI, 1.39–1.47). For patients without comorbidities (72.7%, 95% CI, 70.5–74.7) and those with DM (73.4%, 95% CI, 68.2–76.7), vaccine effectiveness was similar after the booster dose. However, it was reduced in patients with DM associated with other comorbidities (60.5%; 95% CI, 57.5–63.2). The strongest factor associated with booster failure was the omicron variant (aOR = 27.8, 95% CI, 19.9–40.1). Our study revealed that COVID-19 vaccines provided robust protection against death in individuals with DM. However, our findings underscore the need to update vaccines and develop tailored strategies for individuals with diabetes, especially those with additional underlying conditions.


  • Open Access

    Brazil’s Scientific Resilience: Recovering from Decline

    by Hercílio Martelli Júnior, Árlen A.D. DE Sousa, Maria Christina L.A. Oliveira, Daniella R.B. Martelli, Eduardo A. Oliveira

    In a previous report in this journal, we documented a decline in Brazilian science funding over the past decade (Martelli Júnior et al. 2019). This trend was exacerbated during the COVID-19 pandemic, coinciding with a far-right-wing government lacking support for scientific research and public universities (Escobar 2021 , Hallal 2021 ). As anticipated, Brazilian scientific output has decreased significantly, with the median annual growth rate declining from 13% to 4%. This period also marked a decline in Brazil’s global scientific standing, as the country slipped from the 13th position in the global scientific production ranking overtaken by South Korea. Furthermore, the number of postgraduate students has decreased by 21% (Oliveira et al. 2020 , 2022).


  • Open Access

    Vaccine protection against COVID-19-related death in patients with schizophrenia: A retrospective cohort study

    by Fabrício E. S. Oliveira, Hercílio Martelli-Júnior, Enrico A. Colosimo, Ana Cristina Simões e Silva, Cristiane S. Dias, Lilian O. Diniz, Clara C. Pinhati, Stella C. Galante, Fernanda N. Duelis, Laura E. Carvalho, et al.

    The Brazilian Journal of Psychiatry is the official publication of Brazilian Psychiatric Association (Associação Brasileira de Psiquiatria - ABP)


  • The impact of smoking on COVID-19-related mortality: a Brazilian national cohort study

    by Fabrício Emanuel Soares de Oliveira, Maria Christina L. Oliveira, Daniella Reis Barbosa Martelli, Samuel Trezena, Cristina Andrade Sampaio, Enrico A. Colosimo, Eduardo A. Oliveira, Hercílio Martelli Júnior


  • Open Access

    The association between schizophrenia and increased Covid-19 mortality in a cohort of over 2 million people in Brazil

    by Fabrício Emanuel Soares de Oliveira, Samuel Trezena, Daniella Reis Barbosa Martelli, Maria Christina L. Oliveira, Enrico A. Colosimo, Hercílio Martelli Júnior, Eduardo Araújo Oliveira

    To describe the clinical outcomes and risk factors of death related to mental disorders in a cohort of Brazilian hospitalized patients with COVID-19. This retrospective cohort study utilized the Brazilian database SIVEP-Gripe to analyze patients aged ≥18 years who had been hospitalized with COVID-19 between 2020 and 2022. The exposure of interest were mental disorders (anxiety, depression, schizophrenia, and bipolar disorder), identified through self-reported fields. The primary outcome was in-hospital mortality. Covariates included demographic and clinical features. Descriptive statistics, t-tests, chi-square tests, and binary logistic regression were used to analyze the data. A cohort of 2,124,285 patients was included in the analysis, with 23,246 individuals (1.1%) having self-reported mental disorders. Among these mental disorders, depression was the most prevalent (52.3%). The mortality rate of the patients with mental disorders was 30.8%. Analysis of risk factors for mortality revealed that age, gender, region, dyspnea, low oxygen saturation, and comorbidities were associated with an increased risk of death. Patients with schizophrenia had a higher mortality risk (aOR:1.68;95%CI:1.54-1.81). Patients diagnosed with schizophrenia have a greater likelihood of COVID-19- related death than those without mental health conditions. These findings underscore the significant effect of serious mental disorders on COVID-19 mortality.